Chloe Orkin

17.3k total citations · 4 hit papers
168 papers, 6.0k citations indexed

About

Chloe Orkin is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Chloe Orkin has authored 168 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Infectious Diseases, 92 papers in Virology and 45 papers in Epidemiology. Recurrent topics in Chloe Orkin's work include HIV/AIDS drug development and treatment (98 papers), HIV Research and Treatment (81 papers) and HIV/AIDS Research and Interventions (75 papers). Chloe Orkin is often cited by papers focused on HIV/AIDS drug development and treatment (98 papers), HIV Research and Treatment (81 papers) and HIV/AIDS Research and Interventions (75 papers). Chloe Orkin collaborates with scholars based in United Kingdom, United States and France. Chloe Orkin's co-authors include Hans‐Jürgen Stellbrink, Martin Fisher, Jürgen K. Rockstroh, Paul E. Sax, Mark Nelson, Daniel Podzamczer, Adriano Lazzarin, Brian Gazzard, Xuelian Wei and David Dunn and has published in prestigious journals such as The Lancet, JAMA and Nature Communications.

In The Last Decade

Chloe Orkin

157 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

2019 468 citations Chloe Orkin, Frank A. Post et al. Clinical Infectious Diseases profile →
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

2013 404 citations Chloe Orkin et al. profile →
Monkeypox

2022 296 citations Chloe Orkin et al. profile →
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

2017 257 citations Chloe Orkin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chloe Orkin United Kingdom	39	3.8k	2.7k	1.8k	1.8k	885	168	6.0k
Estebán Martínez Spain	47	5.0k 1.3×	3.1k 1.2×	2.4k 1.3×	3.6k 2.0×	774 0.9×	323	8.5k
Jan Gerstoft Denmark	48	4.8k 1.3×	3.6k 1.3×	3.0k 1.6×	3.1k 1.7×	558 0.6×	303	9.2k
Phyllis C. Tien United States	51	3.5k 0.9×	1.9k 0.7×	2.3k 1.3×	4.2k 2.4×	912 1.0×	288	8.2k
John S. Lambert Ireland	38	2.4k 0.6×	1.5k 0.6×	1.7k 0.9×	930 0.5×	616 0.7×	215	4.8k
Diane Aschman United States	7	5.7k 1.5×	3.8k 1.4×	2.9k 1.6×	2.0k 1.1×	445 0.5×	12	7.8k
Kees Brinkman Netherlands	39	3.8k 1.0×	2.3k 0.8×	1.7k 1.0×	2.4k 1.3×	654 0.7×	139	6.0k
Judith A. Aberg United States	51	5.9k 1.6×	2.5k 0.9×	3.0k 1.7×	2.9k 1.6×	543 0.6×	200	9.2k
Martin Rickenbach Switzerland	45	4.7k 1.2×	2.8k 1.0×	2.5k 1.4×	2.0k 1.1×	674 0.8×	117	7.8k
Colette Smith United Kingdom	40	3.7k 1.0×	1.6k 0.6×	2.8k 1.5×	1.6k 0.9×	502 0.6×	233	6.9k
Mark O. Loveless United States	18	6.1k 1.6×	4.1k 1.5×	3.1k 1.7×	2.2k 1.3×	464 0.5×	32	8.8k

Countries citing papers authored by Chloe Orkin

Since Specialization

Citations

This map shows the geographic impact of Chloe Orkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chloe Orkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chloe Orkin more than expected).

Fields of papers citing papers by Chloe Orkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chloe Orkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chloe Orkin. The network helps show where Chloe Orkin may publish in the future.

Co-authorship network of co-authors of Chloe Orkin

This figure shows the co-authorship network connecting the top 25 collaborators of Chloe Orkin. A scholar is included among the top collaborators of Chloe Orkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chloe Orkin. Chloe Orkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pasin, Chloé, et al.. (2025). Outcomes of real‐world initiation of long‐acting injectable cabotegravir and rilpivirine ( LA ‐I CAB + RPV ) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations. HIV Medicine. 27(1). 42–57.

Geretti, Anna María, Marta Boffito, Stefano Bonora, et al.. (2025). Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. Open Forum Infectious Diseases. 12(7). ofaf368–ofaf368. 2 indexed citations

Koprulu, Mine, Eleanor Wheeler, Nicola D. Kerrison, et al.. (2025). Sex differences in the genetic regulation of the human plasma proteome. Nature Communications. 16(1). 4001–4001. 3 indexed citations

Smuk, Melanie, et al.. (2025). Long-Acting Injectable Cabotegravir and Rilpivirine in Observational Cohortstudies: A Systematic Review on Virological Failure, Resistance, and Re-Suppression Outcomes in Virallysuppressed Individuals Living with HIV. SSRN Electronic Journal. 1 indexed citations

Orkin, Chloe, Joanne Haviland, Vanessa Apea, et al.. (2024). Perspectives of People With HIV on Implementing Long-acting Cabotegravir Plus Rilpivirine in Clinics and Community Settings in the United Kingdom: Results From the Antisexist, Antiracist, Antiageist Implementing Long-acting Novel Antiretrovirals Study. Clinical Infectious Diseases. 80(5). 1103–1113. 5 indexed citations

Picchio, Camila A, et al.. (2024). Co-creating a Mpox Elimination Campaign in the WHO European Region: The Central Role of Affected Communities. Open Forum Infectious Diseases. 11(10). ofae523–ofae523. 6 indexed citations

Smuk, Melanie, Sara Paparini, Vanessa Apea, et al.. (2024). Cross-sectional survey of sexual health professionals’ experiences and perceptions of the 2022 mpox outbreak in the UK. BMJ Open. 14(1). e080250–e080250. 7 indexed citations

Peters, Ellen, et al.. (2023). Poster Abstracts. HIV Medicine. 24(S3). 21–106.

Martinello, Marianne, Sanjay Bhagani, David Shaw, et al.. (2023). Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study. JHEP Reports. 5(10). 100867–100867. 4 indexed citations

10.

Dhairyawan, Rageshri, Adrienne Milner, John Thornhill, et al.. (2023). Experiences of initiating rapid antiretroviral therapy among people newly diagnosed with HIV in East London: a qualitative study. Sexually Transmitted Infections. 99(7). 455–460.

11.

Wan, Yize I., Yvonne Gilleece, Rageshri Dhairyawan, et al.. (2023). Gender and ethnicity intersect to reduce participation at a large European hybrid HIV conference. BMJ Leader. 8(3). 227–233. 1 indexed citations

12.

Paparini, Sara, et al.. (2022). Public understanding and awareness of and response to monkeypox virus outbreak: A cross‐sectional survey of the most affected communities in the United Kingdom during the 2022 public health emergency. HIV Medicine. 24(5). 544–557. 42 indexed citations

13.

Mussini, Cristina, Giovanni Guaraldi, & Chloe Orkin. (2022). Monkeypox vaccination—an opportunity for HIV prevention. The Lancet HIV. 9(11). e741–e742. 7 indexed citations

14.

Campbell, Lucy, Fowzia Ibrahim, Chloe Orkin, et al.. (2021). Bone mineral density, kidney function and participant‐reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir. HIV Medicine. 23(4). 362–370. 4 indexed citations

15.

Apea, Vanessa, Yize I. Wan, Rageshri Dhairyawan, et al.. (2021). Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study. BMJ Open. 11(1). e042140–e042140. 70 indexed citations

16.

Ibrahim, Fowzia, Lucy Campbell, Sarah Stockwell, et al.. (2020). Estimated glomerular filtration rate slopes on tenofovir alafenamide. HIV Medicine. 21(9). 607–612. 11 indexed citations

17.

Grenfell, Pippa, et al.. (2019). ‘Just another vial…’: a qualitative study to explore the acceptability and feasibility of routine blood-borne virus testing in an emergency department setting in the UK. BMJ Open. 9(4). e024085–e024085. 11 indexed citations

18.

Cresswell, Fiona V, et al.. (2018). A systematic review of risk of HIV transmission through biting or spitting: implications for policy. HIV Medicine. 19(8). 532–540. 14 indexed citations

19.

Gourlay, Annabelle, Julie Fox, Mitzy Gafos, et al.. (2017). A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England. BMJ Open. 7(8). e016494–e016494. 14 indexed citations

20.

Leen, Clifford, Jonathan Ainsworth, J. Anderson, et al.. (2009). Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? United Kingdom Collaborative HIV Cohort Study Group. UCL Discovery (University College London). 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact